Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Dondi

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular LymphomaStefano Luminari, Angela Ferrari, Martina Manni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 StudyStefano Luminari, Martina Manni, Sara Galimberti, et al.
Haematologica|November 1, 2019
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Fabio Benedetti, Carola Boccomini, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular LymphomaStefano Luminari, Angela Ferrari, Martina Manni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 StudyStefano Luminari, Martina Manni, Sara Galimberti, et al.
Haematologica|November 1, 2019
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Fabio Benedetti, Carola Boccomini, et al.
The Lancet. Haematology|June 27, 2024
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trialAlessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
Pageof 2